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The FoxP3 (forkhead box P3) gene is an X-linked gene that is submitted to inactivation. It is
an essential transcription factor in CD4þCD25þFoxP3 regulatory T cells, which are thera-
peutic targets in disseminated cutaneous melanoma. Moreover, FoxP3 is an important
tumor suppressor gene in carcinomas and has putative cancer suppressor gene function
in cutaneous melanoma as well. Therefore understanding the structure and function of
the FoxP3 gene is crucial to gaining insight into the biology of melanoma to better develop
immunotherapeutics and future therapeutic strategies.
ª 2011 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.After decades of continuous failures, ipilumimab e which
blocks cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4)
was recently demonstrated to improve overall survival in
patients with previously treated metastatic cutaneous mela-
noma. Ipilimumab, with or without a gp100 vaccine, was asso-
ciated with improved survival as compared with gp100 alone
(Hodi et al., 2010). This is the first ever reported positive phase
3 trial in advanced melanoma. Ipilumimab blocks CTLA-4 and
this blockade may improve survival by modifying the intratu-
moral effector/regulatory cell ratio, thus highlighting the im-
portance of regulatory T-lymphocytes (TReg) for melanoma
progression in vivo. CD4þ TReg express the transcription factor
forkhead box P3 (Foxp3), which is essential for their normal
development and function (Fontenot and Rudensky, 2005).
Antigenic stimulation of conventional CD4þ T cells in the
presence of transforming growth factor-b (TGF-b) inducesology, Jewish General Ho
Spatz).
ation of European BiocheFoxP3 expression and the acquisition of suppressor function
(Amarnath et al., 2007; Chen and Konkel, 2010; Fantini et al.,
2004; Floess et al., 2007; Fu et al., 2004; Horwitz et al., 2008;
Huber et al., 2009; Huter et al., 2008; Kawamoto et al., 2010;
Marie et al., 2005; Samanta et al., 2008; Schramm et al., 2004;
Zheng et al., 2006; Zhou et al., 2008a, 2010). It has been clearly
established that stable FoxP3 expression is required to main-
tain suppressive properties of TReg cells (Blache et al., 2009).
Although it is necessary for the continued suppressive action
of functional TReg cells, FoxP3 expression alone is not suffi-
cient to accurately identify functional TReg cells because
post-translational changes in discrete residues of the protein
can lead to loss of function (Li and Greene, 2008). The regu-
lation of FoxP3 expression is essential to modulating immune
surveillance through the regulatory T-cell lineage. The FoxP3
gene has a dual role as it is also an X-linked tumor suppressorspital, 3755 Cote Ste Catherine, Montreal, QC H3T 1E2, Canada.
mical Societies. Published by Elsevier B.V. All rights reserved.
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melanoma has yet to be determined. Understanding the regu-
lation and function of the FoxP3 gene is therefore crucial to
better understanding the biology of melanoma.1. Structure of the FoxP3 gene and regulation by
transcription factors
The FoxP3 gene is located on the X chromosome (chr) at
Xp11.23 and is submitted to X chr inactivation (Bennett
et al., 2001; Wang et al., 2009). The gene contains 11 coding
exons (exons 1e11) and 3 non coding exons (Bennett et al.,
2001). The two 50 non coding exons (2a and 2b) are spliced
into a common non coding exon (1) (Floess et al., 2007;
Kaur et al.,2 010; Smith et al., 2006). The 2b and 1 exons en-
compass regulatory cis-elements. (Lal and Bromberg, 2009;
Lopes et al., 2007). It should be noticed that several reports re-
fer to exon1 as exon 1 and name the exons differently from 1
to 12. An AA insertion in exon 8 leads to the scurfy phenotype
in mice. (Bennett et al., 2001). About 60% of patients with an
IPEX syndrome-immune dysfunction, polyendocrinopathy,
enteropathy, X-linked syndrome have missense mutations
in exons 9, 10, and 11 which encode the forkhead domain
(Bennett et al., 2001; Harbuz et al., 2010; Owen et al., 2003;
Rubio-Cabezas et al., 2009; Torgerson et al., 2007).
The FoxP3 protein is highly conserved (Lal et al., 2009;
Sadlon et al., 2010; Zheng et al., 2010). It is critical to the under-
standing of FoxP3 function to realize that human cells express
three FoxP3 isoforms (Aarts-Riemens et al., 2008; Allan et al.,
2005; Kaur et al., 2010; Smith et al., 2006; Ziegler, 2006) The
longest form resembles the murine FoxP3, whereas the other
two are unique to humans. FoxP3DE2 lacks exon 2, which is
part of the repressor domain in the FoxP3 protein. Compared
to full length FoxP3, expression of FoxP3DE2 in human
CD4þCD25eFoxP3e T cells leads to more IL-2 secretion and
proliferation in response to T-cell receptor (TCR) stimulation
(Allan et al., 2005). It has been proposed that FoxP3DE2 acts
as a dominant negative isoform (Li et al., 2007; Xu et al.,
2010). Human TRegs can also express a third isoform that lacks
both exon 2 and exon 7 (Kaur et al., 2010). The absence of exon
7, which encodes a leucine zipper motif, in the FoxP3DE2D7
isoform abrogates the suppressive function of TRegs (Kaur
et al., 2010). This emphasizes the importance of distinguishing
the FoxP3, FoxP3DE2, and FoxP3DE2D7 isoforms to accurateley
sub-type TRegs.
Conservative noncoding sequences (CNS) are located
within 500 base pairs 50 to the transcription start site and
serve as a proximal promoter region (Zhang et al., 2008). It
contains TATA, GC, and CAAT boxes that, when mutated,
lead to decreased FoxP3 activity (Mantel et al., 2006). This
region also contains binding sites for important transcription
factors, such as nuclear factor of activated T cells (NFAT),
activator protein-1 (AP-1), and Sp-1 that play a role in anti-
CD3/CD28-driven FoxP3 expression (Kim, 2009; Zheng et al.,
2010). The 50 intron 2, located between exon 2a and exon
1, contains a CNS and is referred to as the intronic
enhancer, whereas the CNS situated 5 kb upstream of the
transcriptional start site is referred to as the upstream
enhancer (Lal et al., 2009). The proximal promoter is able tobind with STAT5 and is dependent on IL-2Rb signalling
(Burchill et al., 2007). It has been recently suggested that
STAT5 is required for FoxP3 expression (Burchill et al.,
2007). The second enhancer region (30 CNS enhancer) locates
to þ4301 to þ4500 as identified by luciferase reporter assays
in Jurkat cells (Wu et al., 2006). This enhancer region contains
a CREB/ATF (activating transcription factor) motif that is
capable of binding CREB and maintaining FoxP3 expression
and thus a stable TReg population (Kim and Leonard, 2007).
Binding sites for STAT5 and STAT3 that mediate signalling
of inflammatory cytokines, including IL-2, IL-6, IL-21, and
IL-27, are also located within this enhancer region (Zorn
et al., 2006). It seems that both STAT5 and STAT3 bind to
the same target site, while STAT3 binds with a much lower
affinity. Recently, using mice with specific deletions of the
conservative regions, Zheng et al. have identified another
pioneer CNS (Zheng et al., 2009). It locates to intron 4, which
is between exons 1 and 2, binds c-Rel, and acts to potently
increase the number of TRegs in the thymus and periphery.
In Th1, the IFN-geinduced protein interferon regulatory
factor 1 binds to the FoxP3 proximal promoter and inhibits
FoxP3 expression (Ouaked et al., 2009). In Th2, IL-4 inhibits
FoxP3 expression in peripheral naive CD4þCD25 T cells by
stimulating phosphorylation of STAT6, which binds between
exons 2b and 1 and inhibits TGF-b-induced FoxP3 expres-
sion (Takaki et al., 2008). TGF-b and IL-4 cosignalling induces
IL-9 secretion, leading to the newly identified IL-9þIL-
10þFoxP3 (Th9) subset (Vang et al., 2008).
Polymorphisms of the FoxP3 gene, including single nucleo-
tide polymorphisms (SNP) and microsatellite polymorphisms
have been reported in multiple case-control and cohort stud-
ies, mostly in patients with autoimmune diseases or cancers
and their controls (Lin et al., 2011). Reported polymorphisms
include SNPs in the promoter region, SNPs in the intron
regions, SNPs downstreamof the coding regions, andmicrosa-
tellite polymorphism (GT)n in the promoter region, and TC(n)
in the intron region (Lan et al., 2010). While most of the poly-
morphisms seem to be clinically irrelevant, a few alleles do
show weak clinical correlation with autoimmune diseases,
including SNPs in primary biliary cirrhosis and psoriasis, and
(TC)n microsatellite polymorphisms in autoimmune thyroid
disease (Inoue et al., 2010; Wang et al., 2010a). Overall, there
is a lack of convincing evidence to suggest that any FoxP3 poly-
morphism is clinically significant.2. Epigenetic regulation of FoxP3 expression
It is well-established that methylation of CpG sequences
inhibits acetylation of histones and binding of transcription
factors to DNA, thus resulting in quiescent genes. Demethyla-
tion of CpG sequences and acetylation of histones, on the
other hand, are features of active genes. Such epigenetic
modifications are also observed in the FoxP3 gene. The meth-
ylation status of the CpG residues in the proximal promoter
region plays an essential role in FoxP3 expression (Janson
et al., 2008). Demethylation induced by treatment with 5-
aza-20-deoxycytidine (Aza) leads to FoxP3 expression in
human NK cells (Lal et al., 2009; Moon et al., 2009). Ten to
forty-five percent of the CpG sites in the FoxP3 proximal
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all are demethylated in natural TRegs (Lal and Bromberg, 2009;
Polansky et al., 2008) TGF-b induces demethylation of CpG at
this site in CD4þCD25 T cells (Lal et al., 2009). Multiple CpG
sequences have been identified in the FoxP3 gene, from 50 to
30 as follows: i) within an upstream CNS, 5e6000 bp 50 to the
transcription starting site; ii) within the intronic enhancer,
and iii) within intron 10, between exons 7 and 8 (Floess
et al., 2007; Hansmann et al., 2010; Lal et al., 2009; Polansky
et al., 2010; Zheng et al., 2010). The intronic enhancer contains
a Runx1 binding sequence. When the enhancer is demethy-
lated (i.e. activated), it can be occupied by a FoxP3, Runx1,
and core-binding factor-b complex (Zhang et al., 2008).
TGF-b induces FoxP3 expression in peripheral naive
CD4þCD25 T cells. In addition to TGF-b receptoreinduced
SMAD3 signaling for TReg generation, TGF-b signaling may
also act via TIEG1 and the E3 ubiquitin ligase itch in a ubiqui-
tin-dependent pathway (Venuprasad et al., 2008). TGF-b also
inhibits the phosphorylation of ERK leading to inhibition of
DNA methyltransferase (DNMT) expression; and inhibition
of DNMT with siRNA or DNMT inhibitors leads to FoxP3 ex-
pression in CD4þ T cells, suggesting that inhibition of DNMT
activity plays an important role in FoxP3 expression (Luo
et al., 2008).
The inflammatory cytokine IL-6 suppresses the develop-
ment and function of TRegs. (Lal et al., 2009). Actually, IL-6
both induces DNMT1 expression and enhances its activity.
IL-6 induces STAT3-dependent methylation of the upstream
FoxP3 enhancer by DNMT1 in TRegs, leading to repression of
FoxP3 (Wang et al., 2007). Preactivated CD4þCD25 T cells or
CD4þCD25CD44hi memory T cells express very little FoxP3
after TGF-b stimulation. This is probably the result of high
levels of DNMT1 activity in these cells because inhibition of
DNMT with Aza or deficiency of DNMT1 in T cells leads to
FoxP3 expression, suggesting that regulation of FoxP3 is
tightly controlled by epigenetic modifications in activated
CD4þ T cells (Lal et al., 2009).
Natural TRegs possess demethylated CpGs at the FoxP3
locus and show stable FoxP3 expression, whereas TGF-b-
induced TRegs show methylated CpGs and do not maintain
constitutive FoxP3 expression after restimulation in the
absence of TGF-b (Baron et al., 2007; Floess et al., 2007; Lal
and Bromberg, 2009; Polansky et al., 2008). It has been reported
that a fraction of the FoxP3þCD4þ natural TRegs adoptively
transferred into lymphopenic mice are converted into FoxP3
T cells (Bruinsma et al., 2010) http://www.ncbi.nlm.nih.gov/
pubmed/19174509. Under inflammatory conditions, FoxP3þ
TRegs lose FoxP3 expression and thus suppressive function in
an IL-6edependent manner (Lal et al., 2011) IL-6 and TCR sig-
nalling induce down-regulation of FoxP3 expression and lead
to development of Th17 cells (Maitra et al., 2009) http://
www.ncbi.nlm.nih.gov/pubmed/18585065. One mode of
action of IL-6 is to induce remethylation of CpG DNA at the
upstream enhancer and thus down-regulates FoxP3 expres-
sion in natural TRegs (Lal et al., 2009). Epigenetic inheritance
during the cell cycle is crucial inmaintaining chromatin struc-
ture in cell lineages. But the extrinsic and intrinsic signals that
regulate CpGDNAmethylation and perpetuate the H3methyl-
ation level at the FoxP3 locus from one cell cycle to another are
not yet understood.3. Mechanisms of impaired regulation by
CD4DCD25DFoxP3D regulatory T cells in human
autoimmune diseases
TReg cells, defined by the expression of CD4, CD25 and FoxP3,
have a central role in protecting an individual from autoim-
munity. This role was first identified in mice in which the
absence or depletion of TRegs resulted in the development of
autoimmune gastritis, thyroiditis, diabetes and inflammatory
bowel disease (IBD) (Ochs et al., 2007). Subsequently, numer-
ous studies in animal models of autoimmunity showed that
defects in CD4þCD25þFoxP3þ TRegs contribute to the develop-
ment of autoimmunity and that the disease could be
reversed by the adoptive transfer of TRegs (Buckner, 2010).
The importance of T cell regulation in human disease is high-
lighted by the severe inflammation and autoimmunity that
occurs in individuals who suffer from IPEX. These individuals
develop a broad range of autoantibodies causing insulin-
dependent diabetes, thyroiditis, eczema, hemolytic anemia
and IBD. In the absence of a bone marrow transplant, IPEX
patients die at an early age (Wildin and Freitas, 2005).
In mouse models, the concept that inadequate numbers of
TRegs may contribute to autoimmunity is supported by the
occurrence of aggressive autoimmunity in scurfy mice and is
indirectly implied by the successful treatment of autoimmu-
nity in mice through the adoptive transfer of wild-type TRegs
(Komatsu and Hori, 2007). In addition, there is evidence from
mouse models that, under the appropriate conditions, TRegs
can be induced in the periphery, and that these TRegs may
prevent the development of autoimmunity. Multiple factors
influence the homeostasis and induction of TRegs in the pe-
riphery, including CD28, IL-2, TGF-b and dendritic cells (DCs)
(Buckner, 2010; Buckner and Ziegler, 2008).
Evidence that an inadequate number of TRegs leads to auto-
immunity in humans is most clearly shown in patients with
IPEX, who completely lack TRegs as a result of a mutation in
FoxP3 (Lal and Bromberg, 2009). However, most patients with
autoimmune disease probably have a more modest reduction
in TRegs. In these common diseases, the challenge is to deter-
mine whether the number of TRegs is inadequate at the site of
inflammation and whether this is due to systemic factors or
factors in the local tissue milieu (Buckner, 2010). In human
disease, the task of enumerating TRegs has been complicated
by the presence of multiple TReg subsets and the lack of
a cell marker that is unique to TRegs. Type 1 regulatory T
(TR1) cells are induced in the periphery and suppress T cell
proliferation through the production of interleukin-10 (IL-10)
and TGF-b. TR1 cells do not have a unique cell marker but
are identified by their production of IL-10 and absence of
pro-inflammatory cytokines (Roncarolo and Gregori, 2008;
Veldman et al., 2009). T helper 3 (TH3) cells are a regulatory T
cell population that originates in the periphery and mediates
suppression through the secretion of TGF-b; similar to TR1
cells, they do not have a unique cell surface marker (Carrier
et al., 2007). CD4þCD25þFoxP3þ TRegs can be divided into two
groups: thymus-derived natural TReg cells and periphery-in-
duced adaptive TReg cells. Both populations express FoxP3
and suppress immune responses through contact-dependent
mechanisms and the production of soluble factors, including
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derived CD4þCD25þFoxP3þ TReg cells are stable with respect to
retaining regulatory function and FoxP3 expression in the
periphery. They are unique in that their FoxP3 locus is deme-
thylated and they express the transcription factor Helios
(Fujimoto et al., 2011; Thornton et al., 2010). Adaptive TReg cells
can be induced in the periphery from a CD4þFoxP3 T cell pop-
ulation following T cell receptor stimulation in the presence of
TGF-b (Mahic et al., 2008). It has now become clear that the
FoxP3þ T cell population is composed of several populations
that are defined by the expression of CD25, CD45RA and
FoxP3. Miyara et al. defined these populations as a naive TReg
cell population that is CD25hiCD45RAþFoxP3hi, an effector
TReg cell population that is CD25
hiCD45RAFoxP3hi and
a non-regulatory FoxP3þ population that is CD25hiC-
D45RAFoxP3low (Miyara and Sakaguchi, 2011; Miyara et al.,
2009). Another difficulty is the extent to which the peripheral
blood reflects the global number of TRegs in the body and,more
specifically, their number in inflamed tissues.
TRegs were first defined on the basis of their expression of
CD25, which forms part of the high-affinity IL-2 receptor. Un-
fortunately, the definition of TRegs based on the level of CD25
expression has not been consistently reported in the litera-
ture, making comparisons between studies difficult. Further-
more, CD25 is also expressed by recently activated T cells,
resulting in the inclusion of CD4þCD25þ effector T cells in
the TReg population (Buckner, 2010). With the discovery that
expression of FoxP3 plays a central role in the differentiation
and maintenance of TRegs, the use of flow cytometry-based
analysis of FoxP3 expression in T cells became the gold stan-
dard for defining TRegs. However, it then became evident that
FoxP3 can also be expressed by effector T cells following acti-
vation, thus any assessment of TRegs number or function is
likely tainted by inclusion of recently activated effector T cells
in the TRegs population. Furthermore, as FoxP3 is a nuclear
protein, assessment of its expression in T cells requires fixa-
tion and permeabilization of the cells, resulting in an inability
to obtain viable cells for further functional analysis. In the
past few years, additional markers, such as CD127 have been
identified that assist in the distinction of effector T cells
from TRegs and facilitate the experimental purification of TRegs
(Simonetta et al., 2010).
In the context of anti-CTLA-4 melanoma therapy, a major
challenge is to measure resistance of effector T cells to sup-
pression. The resistance of effector T cells to TRegs has been
observed in several animal models of autoimmunity (Chen
et al., 2010; Schneider et al., 2008). In these models, inflamma-
tion and tissue destruction progress despite the presence of
functional TRegs at the site of inflammation. Such findings sug-
gest that a resistance of effector T cells to TRegsmay contribute
to autoimmunity. Whether this might be of interest to predict
response to anti-CTLA-4 therapy needs further investigation.4. FoxP3 as an X-linked tumor suppressor gene
Foxp3 is expressed in epithelial cells from various organs such
as breast, thymus, prostate and lung. Importantly, mice that
are heterozygous for FoxP3 mutations spontaneously develop
mammary carcinomas at a high frequency (Chen et al., 2008).Genetic analyses in both mice and humans revealed that
Foxp3 is an important X-linked tumor suppressor in breast
and in prostate cancer (Gupta et al., 2007; Karanikas et al.,
2008; Katoh et al., 2010; Kiniwa et al., 2007; Ladoire et al., 2011;
Li et al., 2011; Liu and Zheng, 2007; Mahmoud et al., 2010;
Merlo et al., 2009; Valdman et al., 2010; Wang et al., 2009,
2010b; Yokokawa et al., 2008; Zuo et al., 2007a, 2007b). Mice
with germline FoxP3 mutations are substantially more prone
to developing both spontaneous and carcinogen-induced
mammary carcinomas (Zuo et al., 2007b). The role of the FoxP3
gene in mammary carcinogenesis has been supported by
several linesof evidence. The FoxP3gene is expressed innormal
breast epithelia but is down-regulated in mammary cancer.
EctopicexpressionofFoxP3 inavarietyofbreastcancercell lines
resulted in cell cycle arrest and cessation of cell growth
(Zuo et al., 2007a). Moreover, FoxP3 directly regulates transcrip-
tion of ErbB2, Skp2 and CDKN1A (p21) (Katoh et al., 2010).
Frequent chromosomal deletions and somatic mutations of
the FoxP3 genewere detected in human cancer samples includ-
ing cutaneous melanomas (Fujii et al., 2010; Karanikas et al.,
2008; ). There is a down-regulation of FoxP3 protein in cancer
cells compared to normal breast epithelia. The FoxP3 gene also
plays an important role in prostate epithelia. Among human
prostate cancers, frequent chromosomal deletions, somatic
mutations and epigenetic silencing of the FoxP3 gene were
found (Li et al., 2011; Wang et al., 2009, 2010b). Since the FoxP3
gene is located on the X chromosome, a genetic/epigenetic sin-
gle-hit results in inactivationof this gene inmales, escaping the
Knudson model (Spatz et al., 2004). Immunohistochemistry
revealed that FoxP3 expression is significantly down-regulated
incancercellswhencompared tonormalprostateglands (Vald-
man et al., 2010). Moreover, mice with prostate-specific abla-
tions of FoxP3, FoxP3fl/y; PB-Creþ, developed prostatic
hyperplasia and prostatic intraepithelial neoplasm (PIN) that
are putative pre-cancerous lesions of the prostate (Ebelt et al.,
2009; Wang et al., 2009). In human samples, FoxP3 expression
in PINs are down-regulated compared to adjacent normal pros-
tate glands, which suggests that the inactivation of the FoxP3
gene plays an important role in the initial stage of prostatic car-
cinogenesis (Ebelt et al., 2009).
Another interesting aspect of FoxP3 abnormalities is that
some types of cancers predominantly express splice variants
of the FoxP3 protein in addition to those occurring in non-
transformed cells (FoxP3, FoxP3DE2, and FoxP3DE2D7). In cuta-
neous melanomas, and in some breast and ovarian cancers,
and malignant T cells of Sezary syndrome, specific splice var-
iants of the FoxP3, such as DE3, DE3e4, DE3/8 and DE8, were
reported to be preferably expressed (Kaur et al., 2010; Smith
et al., 2006) The D3e4 splice variant results in a truncated
FoxP3 with a premature stop codon, and therefore might con-
tribute to the malignant progression of cells (Wang et al.,
2009). Whereas FoxP3 has been shown to up-regulate CTLA-4
expression, it is not known whether different variants in the
primary melanoma are associated with different responses
to ipilimumab at a later stage.
Expression of the oncogene c-MYC has been demonstrated
to be directly repressed by FoxP3 in prostate epithelia (Wang
et al., 2009). Overexpression of c-MYC contributes to more
aggressive and poorly differentiated cancer phenotypes and
has been involved in the biology of melanoma. c-MYC is a
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player in various cellular processes including cell cycle and
apoptosis; processes which are also dysregulated in cancer
cells with high c-MYC expression levels. C-MYC directly acti-
vates CDK4 and CCND2 expression, while indirectly repressing
CDK inhibitors such as CDKN1A ( p21) and CDKN2B ( p15)
expression (Wang et al., 2011). Moreover, c-MYC directly up-
regulates eIF4E and eIF2a; both of which are the rate-limiting
effectors of cell cycle.
HER2 is a member of the transmembrane receptor tyrosine
kinases and is involved in the regulations of various cellular
functions such as cell growth and survival. The cytoplasmic
portion of HER2 is phosphorylated at conserved tyrosine res-
idues and these phosphorylated tyrosines can serve as bind-
ing sites for adapters which link HER2 to its downstream
pathways or targets such as PI3K-Akt and MAPK-Erk. Both
HER2 gene amplification and loss of nuclear FoxP3 contribute
to HER2 overexpression in breast cancer samples (Mahmoud
et al., 2010; Zhou et al., 2008b). FoxP3 can repress transcrip-
tion of HER2 in human breast cancers by binding directly to
the ERBB2 gene promoter (Zhou et al., 2008b). Since in vitro
HER2 overexpression nullifies the ability of FoxP3 to inhibit
cell growth, repression of HER2 may be critical for the tumor
suppressor function of FoxP3 in the breast epithelial cells
(Zuo et al., 2007a). Maybe this can partially explain why circu-
lating CD4þCD25þFoxP3þ TRegs decrease in breast cancer pa-
tients after vaccination with a modified MHC class II HER2/
neu peptide (Gates et al., 2010). Recently it has been demon-
strated that the influence of FoxP3 was dependent on the
molecular sub-type of breast cancer. Indeed, FoxP3 expres-
sion in cancer cells may be a marker of good prognosis in
HER2-overexpressing tumors and of poor prognosis in other
molecular sub-types of breast cancer (Ladoire et al., 2011).
High levels of expression of SKP2 have been reported in
a wide variety of cancers including melanoma (Katagiri
et al., 2006; Rose et al., 2011). SKP2 is an important player in
the ubiquitin-dependent degradation of p27KIP1, a CDK inhibi-
tor especially of Cyclin-E/CDK2 and Cyclin-A/CDK2 (Katagiri
et al., 2006; Rose et al., 2011). SKP2 is robustly expressed during
S and G2 phases of the cell cycle and regulates p27 degrada-
tion, thus facilitating progression of the cell cycle. It has
been demonstrated that FoxP3 directly represses SKP2 expres-
sion in human and mouse mammary epithelial cells (Zuo
et al., 2007a). FoxP3 occupies the Skp2 promoter and represses
promoter activity of the locus (Zuo et al., 2007a). FoxP3 directly
regulates keymolecules of cell cycle regulation, which further
supports the notion that FoxP3 is an important tumor
suppressor.
Previous reports have revealed that FoxP3 forms complexes
with Rel family transcription factors NFAT and NFkB, and
FoxP3 blocks their ability to activate Il-2 and INFg transcription
(Ruan et al., 2009; Soligo et al., 2011). By making a repressive
FoxP3:NFAT complex, FoxP3 inhibits NFAT:AP-1 complex at
the Il-2 promoter (Kim, 2009). FoxP3 could also weaken the
DNA binding activity of AP-1 (Lee et al., 2008). AML1/RUNX1,
which activates endogenous Il-2 and IFNg expression in CD4þ
T cells, is reported to make a complex with FoxP3. (Hancock
and Ozkaynak, 2009; Ono et al., 2007). AML1/RUNX1 could
bind to the Il-2 enhancer with FoxP3 and exert optimal repres-
sion of Il-2 in TRegs (Ono et al., 2007).5. Conclusion
The FoxP3 gene has important functions as a tumor suppres-
sor gene in human carcinomas and recent data suggests it
plays a role in melanoma as well. At the same time, this
gene directly commands the natural regulatory T cells that
have been demonstrated to be an effective target for mela-
noma therapy. Thus an interesting issue is whether FoxP3
gene is a friend or a foe for melanoma therapy. Perhaps gain-
ing better insight about the roles of aberrantly spliced vari-
ants will be the first step in answering this question.
Although molecular mechanisms have not yet been clarified,
some agents have been reported to increase FoxP3 in cancer
cells. Anisomycin could induce the transcription of FoxP3 in
various breast cancer cell lines, resulting in significantly
repressed cell growth in vitro and in xenografts in vivo (Liu
et al., 2009). In breast and colon cancer cell lines, FoxP3
expression is directly regulated by p53. Doxorubicin, which
activates p53, dramatically activates FoxP3 transcription in
vitro (Jung et al., 2010). Maybe the restoration of FoxP3 func-
tions in melanoma cells with low FoxP3 expression or DE3/
DE3DE4 variants combined with anti-CTLA-4 therapy could
have potential as a novel therapeutic strategy. Identification
of these variants could also be of help in discovering the first
predictive biomarker for anti-CTLA-4 therapy. It will also
likely enable improved development of effective combina-
tions of immunotherapy and targeted therapy.
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